The Beijing Municipal Science and Technology Commission and the Zhongguancun Science Park Management Committee have announced the list of key laboratories to be recognized in 2025. Chinese Institutes for Medical Research (CIMR), Beijing has successfully secured approval for two key laboratories: the "Beijing Key Laboratory of Tumor Resistance Mechanisms and Clinical Translation" and the "Beijing Key Laboratory of Autoimmune Disease Mechanisms and New Drug Development".

 

The Beijing Key Laboratory of Tumor Resistance Mechanism and Clinical Translation, affiliated with the Chinese Institutes for Medical Research (CIMR), is jointly established with Beijing Friendship Hospital, Beijing Chest Hospital, Beijing DP Technology Co., Ltd., and Hebei Senlang Biotechnology Co., Ltd. Focusing on the core bottleneck of cancer treatment—tumor drug resistance—the laboratory deeply integrates its rich experience and multifaceted advantages in basic research, clinical diagnosis and treatment, AI empowerment, and drug development. It is committed to building a three-tiered collaborative system for tumor research in the Beijing-Tianjin-Hebei region, encompassing basic mechanisms, AI-driven approaches, and clinical translation. The laboratory is dedicated to constructing a tumor drug resistance library, exploring the molecular mechanisms of tumor drug resistance, developing personalized treatment decision support systems, actively promoting the rapid deployment of innovative drugs, and comprehensively advancing the development of tumor diagnosis and treatment.

 

Under the leadership of Professor Shao-Cong Sun, Distinguished Investigator and Director of Chinese Institute for Immunologyy at CIMR, and in collaboration with Beijing Chaoyang Hospital, this laboratory focuses on the precise diagnosis and innovative drug development for autoimmune diseases. The goal is to create a world-class center for interdisciplinary research and clinical translation in autoimmune diseases. By integrating expertise in immunology, molecular medicine, and clinical resources, the laboratory aims to build an integrated platform that encompasses pathogenesis analysis, biomarker discovery, new disease identification, and new drug development. The laboratory's research directions are: 1. Autoimmune Tolerance Mechanisms: Investigate the mechanisms of immune homeostasis imbalance, identify key pathogenic cells and signaling pathways, and characterize autoantigens; 2. Biomarker Research: Develop early diagnostic and classification biomarker systems and identify novel autoimmune diseases; 3. New Drug Development for Autoimmune Diseases: Focus on developing next-generation, safe, and effective immunotherapies, including CAR-T/NKT/Treg cell therapies, antibody drugs, and small-molecule targeted drugs.